Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iovance Biotherapeutics, Inc.    IOVA

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
51.09(c) 49.7(c) 50.63(c) 52.03(c) 51.06(c) Last
1 576 716 1 119 397 882 821 1 230 946 981 905 Volume
+1.13% -2.72% +1.87% +2.77% -1.86% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -257 M - -
Net cash position 2020 662 M - -
P/E ratio 2020 -27,7x
Yield 2020 -
Sales 2021 1,55 M - -
Net income 2021 -302 M - -
Net cash position 2021 422 M - -
P/E ratio 2021 -24,9x
Yield 2021 -
Capitalization 7 490 M 7 490 M -
EV / Sales 2020 -
EV / Sales 2021 4 571x
Nbr of Employees 148
Free-Float 92,4%
More Financials
Company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2... 
More about the company
Notations Surperformance© of Iovance Biotherapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about IOVANCE BIOTHERAPEUTICS, INC.
01/14IOVANCE BIOTHERAPEUTICS : Oppenheimer Adjusts Iovance Biotherapeutics PT to $57 ..
MT
01/07IOVANCE BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits ..
AQ
2020Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare ..
GL
2020IOVANCE BIOTHERAPEUTICS : Barclays Adjusts Price Target for Iovance Biotherapeut..
MT
2020IOVANCE BIOTHERAPEUTICS : HC Wainwright Downgrades Iovance Biotherapeutics to Ne..
MT
2020IOVANCE BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers, Other..
AQ
2020IOVANCE BIOTHERAPEUTICS : Taps Jean-Marc Bellemin for Finance Chief
MT
2020IOVANCE BIOTHERAPEUTICS : Appoints Jean-Marc Bellemin as Chief Financial Officer
AQ
2020Iovance Biotherapeutics to Present at Upcoming Conferences in December
GL
2020IOVANCE BIOTHERAPEUTICS : Presents Clinical Data in Head and Neck Cancer at Soci..
AQ
2020JMP Securities Adjusts Iovance Biotherapeutics' Price Target to $45 From $38,..
MT
2020IOVANCE BIOTHERAPEUTICS : Corporate Presentation
PU
2020IOVANCE BIOTHERAPEUTICS : Presents Clinical Data in Head and Neck Cancer at Soci..
AQ
2020Iovance Biotherapeutics Presents Clinical Data in Head and Neck Cancer at Soc..
GL
2020IOVANCE BIOTHERAPEUTICS : Reports third quarter and year-to-date 2020 financial ..
AQ
More news
News in other languages on IOVANCE BIOTHERAPEUTICS, INC.
2020EN DIRECT DES MARCHES : Thales, Danone, Peugeot, Europcar, Ingenico, Disney, ..
2020STOCK MARKET PARIS : Rester sur le marché ou le quitter, telle est la question
2020EN DIRECT DES MARCHES : Renault, Peugeot, Casino, Vivendi, Bourbon, Gaumont, ..
2020STOCK MARKET PARIS : L'accord commercial Chine / Etats-Unis se profile
More news
Analyst Recommendations on IOVANCE BIOTHERAPEUTICS, INC.
More recommendations
Chart IOVANCE BIOTHERAPEUTICS, INC.
Duration : Period :
Iovance Biotherapeutics, Inc. Technical Analysis Chart | IOVA | US4622601007 | MarketScreener
Technical analysis trends IOVANCE BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 52,00 $
Last Close Price 51,06 $
Spread / Highest target 17,5%
Spread / Average Target 1,84%
Spread / Lowest Target -31,5%
EPS Revisions
Managers and Directors
NameTitle
Maria Fardis President, Chief Executive Officer & Director
Iain David Dukes Chairman
Jean-Marc Bellemin Chief Financial Officer & Treasurer
Friedrich Graf Finckenstein Chief Medical Officer
Merrill A. McPeak Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
IOVANCE BIOTHERAPEUTICS, INC.10.04%7 490
EXACT SCIENCES CORPORATION10.17%23 214
GUARDANT HEALTH, INC.23.60%15 925
INVITAE CORPORATION25.78%9 293
ADAPTIVE BIOTECHNOLOGIES CORPORATION10.08%8 903
BGI GENOMICS CO., LTD.13.25%8 900